Showing 1161-1170 of 2040 results for "".
- DEKA Medical Receives FDA Clearance for the Synchro REPLA:Yhttps://practicaldermatology.com/news/20140213-deka_medical_receives_fda_clearance_for_the_synchro_replay/2459343/The FDA cleared DEKA Medical, Inc.'s Synchro REPLA:Y, an aesthetic workstation dedicated, but not limited, to high speed stable long-term, or permanent hair reduction, treatment of PFB, treatment of benign pigmented lesions, treatment of wrinkles and
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s
- Restoration's ARTAS Earns Edison Gold Medal for Innovationhttps://practicaldermatology.com/news/20130430-restorations_artas_earns_edison_gold_medal_for_innovation/2459554/Restoration Robotics, Inc.'s ARTAS® System was honored with the Gold medal at the 26th Edison Awards, the international awards ceremony honoring innovators and innovation, in the science/medical category. The Edison Awards celebrate human creati
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Data Suggest Makucell's Asymmtate Reverses Gene Expression in Aging Skinhttps://practicaldermatology.com/news/20120725-makucell_announces_results_on_proprietary_technology_asymmtate/2459765/Makucell, Inc.'s Asymmtate(TM), the key ingredient in the Renewnt line, may reverse gene expression changes associated with aging skin and with lentigines. Findings for Asymmtate, a proprietary cosmetic ingredient that influences the gene co-act
- Nathalie Daste Named LEO Pharma’s New Executive Vice President of Global People and Corporate Affairshttps://practicaldermatology.com/news/nathalie-daste-named-leo-pharmas-new-executive-vice-president-of-global-people-and-corporate-affairs/2461964/Nathalie Daste is LEO Pharma’s new Executive Vice President, Global People and Corporate Affairs, and member of its Global Leadership Team, effective October 1, 2023. In her new role, Ms. Daste will head LEO Pharma’s Global People function as well as Corporate Affa
- Burt's Bees Products Improve Redness, Pigmentation, and Reduce Acne-related PIHhttps://practicaldermatology.com/news/burts-bees-products-improve-redness-pigmentation-and-reduce-acne-related-pih/2461624/Burt’s Bees topical bakuchiol-containing sunscreen treats redness and pigmentation of photodamaged facial skin. What’s more, a cream containing Glycyrrhiza glabra (licorice root), Curcuma longa (turmeric root), and Terminalia chebula improves&n
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pha